creatine has been researched along with Alcoholism in 31 studies
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 7.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Acamprosate is approved for the treatment of alcoholism, but its mechanism of action remains unclear." | 5.14 | Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. ( Adams, LJ; Doty, L; George, DT; Heilig, M; Hommer, D; Lifshitz, M; Momenan, R; Schwandt, ML; Shen, J; Singley, E; Spanagel, R; Umhau, JC; Vengeliene, V; Zhang, Y, 2010) |
| "Concentrations of N-acetylaspartate, choline-containing compounds, myo-inositol, and creatine plus phosphocreatine in frontal lobe gray matter and white matter were estimated in eight women and 17 men who were recently detoxified from long-term alcoholism." | 3.72 | Effects of alcoholism and gender on brain metabolism. ( Alhassoon, OM; Brown, GG; Gonzalez, R; Grant, I; Patterson, TL; Schweinsburg, BC; Taylor, MJ; Videen, JS, 2003) |
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 3.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Posttraumatic stress disorder (PTSD) patients have low cortical concentrations of γ-aminobutyric acid (GABA) and elevated glutamate (Glu) as measured by proton magnetic resonance spectroscopy ((1)H MRS)." | 1.40 | A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. ( Abé, C; Batki, SL; Meyerhoff, DJ; Pennington, DL, 2014) |
| "Chronic alcoholism is associated with altered brain metabolism, morphology and cognitive abilities." | 1.37 | Brain metabolite changes in alcoholism: localized proton magnetic resonance spectroscopy study of the occipital lobe. ( Bhattacharya, M; Deshpande, SN; Khushu, S; Kumar, P; Modi, S; Tripathi, RP, 2011) |
| "Alcoholism is highly prevalent among bipolar disorder (BD) patients, and its presence is associated with a worse outcome and refractoriness to treatment of the mood disorder." | 1.36 | Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. ( Chen, HH; Hatch, JP; Lafer, B; Monkul, ES; Nery, FG; Nicoletti, MA; Soares, JC; Stanley, JA, 2010) |
| "Recent studies demonstrated that alcohol dependence and excessive alcohol consumption are associated with increased rates of obesity." | 1.36 | Body mass index is associated with brain metabolite levels in alcohol dependence--a multimodal magnetic resonance study. ( Durazzo, TC; Gazdzinski, S; Meyerhoff, DJ; Mon, A, 2010) |
| "Co-morbidities of PTSD, notably alcohol abuse, may have contributed to the inconsistency." | 1.35 | Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. ( Fox-Bosetti, S; Kornak, J; Lenoci, M; Marmar, CR; Neylan, TC; Samuelson, KW; Schuff, N; Studholme, C; Weiner, MW, 2008) |
| "Chronic alcohol abuse results in morphological, metabolic, and functional brain damage which may, to some extent, be reversible with early effects upon abstinence." | 1.34 | Manifestations of early brain recovery associated with abstinence from alcoholism. ( Bartsch, AJ; Bendszus, M; Biller, A; De Stefano, N; Homola, G; Jenkinson, M; Smith, SM; Solymosi, L; Weijers, HG; Wiesbeck, GA, 2007) |
| "The alcohol addiction was the most common among men (68." | 1.32 | [Clinical aspects of acute intoxication with ethanol]. ( Chodorowski, Z; Ciechanowicz, R; Kujawska, H; Sein Anand, J; Wiśniewski, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.90) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 10 (32.26) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Grodin, EN | 1 |
| Nieto, SJ | 1 |
| Meredith, LR | 1 |
| Burnette, E | 1 |
| O'Neill, J | 1 |
| Alger, J | 1 |
| London, ED | 1 |
| Miotto, K | 1 |
| Evans, CJ | 1 |
| Irwin, MR | 1 |
| Ray, LA | 1 |
| Durazzo, TC | 3 |
| McNerney, MW | 1 |
| Hansen, AM | 1 |
| Gu, M | 1 |
| Sacchet, MD | 1 |
| Padula, CB | 1 |
| Streit, F | 1 |
| Treutlein, J | 1 |
| Frischknecht, U | 1 |
| Hermann, D | 2 |
| Mann, K | 2 |
| Kiefer, F | 1 |
| Sack, M | 1 |
| Hall, ASM | 1 |
| Frank, J | 1 |
| Witt, SH | 1 |
| Foo, JC | 1 |
| Degenhardt, F | 1 |
| Heilmann-Heimbach, S | 1 |
| Nöthen, MM | 1 |
| Sommer, WH | 1 |
| Spanagel, R | 2 |
| Rietschel, M | 1 |
| Ende, G | 2 |
| Pennington, DL | 1 |
| Abé, C | 1 |
| Batki, SL | 1 |
| Meyerhoff, DJ | 4 |
| Zahr, NM | 2 |
| Carr, RA | 1 |
| Rohlfing, T | 2 |
| Mayer, D | 2 |
| Sullivan, EV | 3 |
| Colrain, IM | 1 |
| Pfefferbaum, A | 3 |
| Machado, A | 1 |
| Soares-Fernandes, J | 1 |
| Ribeiro, M | 1 |
| Rodrigues, M | 1 |
| Cerqueira, J | 1 |
| Ferreira, C | 1 |
| Nery, FG | 1 |
| Stanley, JA | 1 |
| Chen, HH | 1 |
| Hatch, JP | 1 |
| Nicoletti, MA | 1 |
| Monkul, ES | 1 |
| Lafer, B | 1 |
| Soares, JC | 1 |
| Modi, S | 1 |
| Bhattacharya, M | 1 |
| Kumar, P | 1 |
| Deshpande, SN | 1 |
| Tripathi, RP | 1 |
| Khushu, S | 1 |
| Hasak, MP | 1 |
| Hsu, O | 1 |
| Vinco, S | 1 |
| Orduna, J | 1 |
| Luong, R | 1 |
| Licata, SC | 1 |
| Renshaw, PF | 1 |
| Pathak, V | 1 |
| Gazdzinski, S | 2 |
| Mon, A | 2 |
| Umhau, JC | 1 |
| Momenan, R | 1 |
| Schwandt, ML | 1 |
| Singley, E | 1 |
| Lifshitz, M | 1 |
| Doty, L | 1 |
| Adams, LJ | 1 |
| Vengeliene, V | 1 |
| Zhang, Y | 1 |
| Shen, J | 1 |
| George, DT | 1 |
| Hommer, D | 1 |
| Heilig, M | 1 |
| Schweinsburg, BC | 2 |
| Alhassoon, OM | 2 |
| Taylor, MJ | 2 |
| Gonzalez, R | 1 |
| Videen, JS | 2 |
| Brown, GG | 2 |
| Patterson, TL | 2 |
| Grant, I | 2 |
| Lee, H | 1 |
| Holburn, GH | 1 |
| Price, RR | 1 |
| Nomoto, N | 1 |
| Arasaki, K | 1 |
| Tamaki, M | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Kujawska, H | 1 |
| Wiśniewski, M | 1 |
| Ciechanowicz, R | 1 |
| Adalsteinsson, E | 1 |
| Welzel, H | 1 |
| Walter, S | 1 |
| Weber-Fahr, W | 1 |
| Diehl, A | 1 |
| Heinz, A | 1 |
| Mason, GF | 2 |
| Petrakis, IL | 1 |
| de Graaf, RA | 1 |
| Gueorguieva, R | 1 |
| Guidone, E | 1 |
| Coric, V | 1 |
| Epperson, CN | 1 |
| Rothman, DL | 1 |
| Krystal, JH | 1 |
| Schuff, N | 2 |
| Mueller, S | 1 |
| Chao, L | 1 |
| Sacrey, DT | 1 |
| Laxer, K | 1 |
| Weiner, MW | 2 |
| Bartsch, AJ | 1 |
| Homola, G | 1 |
| Biller, A | 1 |
| Smith, SM | 1 |
| Weijers, HG | 1 |
| Wiesbeck, GA | 1 |
| Jenkinson, M | 1 |
| De Stefano, N | 1 |
| Solymosi, L | 1 |
| Bendszus, M | 1 |
| Lee, E | 1 |
| Jang, DP | 1 |
| Kim, JJ | 1 |
| An, SK | 1 |
| Park, S | 1 |
| Kim, IY | 1 |
| Kim, SI | 1 |
| Yoon, KJ | 1 |
| Namkoong, K | 1 |
| Neylan, TC | 1 |
| Fox-Bosetti, S | 1 |
| Lenoci, M | 1 |
| Samuelson, KW | 1 |
| Studholme, C | 1 |
| Kornak, J | 1 |
| Marmar, CR | 1 |
| Hickman, R | 1 |
| Saunders, SJ | 1 |
| Eales, L | 1 |
| Losowsky, MS | 1 |
| Leonard, PJ | 1 |
| Berger, F | 1 |
| Vary, TC | 1 |
| Lynch, CJ | 1 |
| Lang, CH | 1 |
| Rumpf, KW | 1 |
| Henze, T | 1 |
| Kaiser, H | 1 |
| Klein, H | 1 |
| Spaar, U | 1 |
| Soballa, R | 1 |
| Prange, H | 1 |
| Henning, HV | 1 |
| Scheler, F | 1 |
| Mullane, JF | 1 |
| Gliedman, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal[NCT00106106] | Phase 2 | 56 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction[NCT01954966] | Phase 4 | 81 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 25
| Intervention | Ratio of glutamate to creatine (Mean) |
|---|---|
| Placebo | 1.350375 |
| Acamprosate | 1.166667 |
The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 4
| Intervention | Ratio of glutamate to creatine (Mean) |
|---|---|
| Placebo | 1.256772 |
| Acamprosate | 1.294178 |
Craving will be assessed using the Brief Questionnaire on Smoking Urges (BQSU). It ranges from 7-70 with higher levels indicating higher levels of nicotine craving. (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 1; post-1st smoking session | Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 40.89 | 30.45 | 38.47 | 38.81 | 41.91 | 40.84 | 40.90 | 39.23 | 41.95 | 27.64 |
| Progesterone 200 mg Look-alike Capsules | 41.94 | 25.77 | 34.34 | 37.98 | 41.82 | 42.03 | 40.29 | 37.68 | 42.38 | 28.22 |
"GABA concentrations (collected in the Dorsal Anterior Cingulate Cortex [DACC]) will be obtained using the non-invasive neuroimaging method of proton magnetic resonance spectroscopy (1H-MRS) both before and after placebo administration and smoking abstinence. In total subjects will undergo 6 1H-MRS scans. The 6 1H-MRS scans take place over a period of approximately 1-2 months. Each paradigm (placebo/progesterone) takes approximately one week, with an approximately two-week wash in between paradigms for men and an approximately 1-month wash in between paradigms for women. The subject will undergo a smoking session on Test Day #1 and Test Day #5, MRS scans are conducted on Test Day #2 (2 scans) and Test Day #5 (1 scan).~Minimal data is available for the primary outcome due to substantial issues with the 7T scanner. All subsequent scans were conducted on a 3T scanner which does not have the capacity to collect data on GABA." (NCT01954966)
Timeframe: Test Day #2 and Test Day #5 - 6 total scans over the period of 2-3 months.
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Test day 2 (baseline, pre-scan) | Test day 2 (post-scan) | Test day 5 (pre-smoking) | |
| Progesterone 200 mg Capsules | 1.23 | 1.28 | 1.21 |
| Progesterone 200 mg Look-alike Capsules | 1.17 | 1.24 | 1.17 |
"GABA concentrations (collected in the Dorsolateral Pre-Frontal Cortex [DLPFC]) will be obtained using the non-invasive neuroimaging method of proton magnetic resonance spectroscopy (1H-MRS) both before and after placebo administration and smoking abstinence. In total subjects will undergo 6 1H-MRS scans. The 6 1H-MRS scans take place over a period of approximately 1-2 months. Each paradigm (placebo/progesterone) takes approximately one week, with an approximately two-week wash in between paradigms for men and an approximately 1-month wash in between paradigms for women. The subject will undergo a smoking session on Test Day #1 and Test Day #5, MRS scans are conducted on Test Day #2 (2 scans) and Test Day #5 (1 scan).~Minimal data is available for the primary outcome due to substantial issues with the 7T scanner. All subsequent scans were conducted on a 3T scanner which does not have the capacity to collect data on GABA." (NCT01954966)
Timeframe: Test Day #2 and Test Day #5 - 6 total scans over the period of 2-3 months.
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Day 2- pre scan | Day 2- post scan | Day 5- after scan, pre smoking | |
| Progesterone 200 mg Capsules | 1.18 | 1.05 | 1.06 |
| Progesterone 200 mg Look-alike Capsules | 1.20 | 0.98 | 1.11 |
Nicotine Effects Questionnaire (NEQ) question: feels bad effects of nicotine. Score ranges from 0 to 100 with higher levels indicating feeling more bad effects of nicotine after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 26.25 | 25.39 |
| Progesterone 200 mg Look-alike Capsules | 25.92 | 28.70 |
NEQ question: feels good effects of nicotine. Score ranges from 0 to 100 with higher levels indicating feeling more good effects of nicotine after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 67.72 | 67.84 |
| Progesterone 200 mg Look-alike Capsules | 67.84 | 64.72 |
Nicotine Effects Questionnaire (NEQ) question: feels strength of nicotine. Score ranges from 0 to 100 with higher levels indicating feeling stronger effects of nicotine after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 71.45 | 74.87 |
| Progesterone 200 mg Look-alike Capsules | 71.01 | 75.25 |
Nicotine Effects Questionnaire (NEQ) question: feels head rush. Score ranges from 0 to 100 with higher levels indicating feeling stronger/more intense head rush after smoking. (NCT01954966)
Timeframe: Day 1 (pre smoking session), Day 5 (post smoking session)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 1; pre-1st smoking session | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 30.58 | 40.23 |
| Progesterone 200 mg Look-alike Capsules | 29.38 | 42.48 |
Positive and Negative Affect Schedule (PANAS) Negative Affect Score. Ranges from 10-50 with higher scores representing higher levels of negative affect. (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 1; post-1st smoking session | Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 11.94 | 10.64 | 11.25 | 11.59 | 12.31 | 13.07 | 12.51 | 12.90 | 12.55 | 11.41 |
| Progesterone 200 mg Look-alike Capsules | 11.43 | 10.57 | 11.03 | 11.49 | 13.01 | 12.89 | 13.06 | 13.16 | 12.18 | 11.94 |
Positive and Negative Affect Schedule (PANAS) Positive Affect Score. Ranges from 10-50 with higher scores representing higher levels of positive affect. (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 1; post-1st smoking session | Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 37.10 | 35.72 | 36.08 | 33.51 | 32.57 | 32.34 | 32.56 | 33.25 | 33.45 | 33.10 |
| Progesterone 200 mg Look-alike Capsules | 37.23 | 36.11 | 36.55 | 34.17 | 33.30 | 32.81 | 32.03 | 32.61 | 32.53 | 33.76 |
Profile of Mood State (POMS) Subscale: Vigor. Subscale ranges from 0 to 32, with higher levels indicating higher levels of vigor. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 18.71 | 16.74 | 16.71 |
| Progesterone 200 mg Look-alike Capsules | 18.71 | 16.73 | 16.39 |
Profile of Mood States (POMS) Subscale: Anger-Hostility. This scale ranges from 0 to 48 with higher levels indicating higher levels of anger/hostility. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 0.94 | 1.55 | 2.70 |
| Progesterone 200 mg Look-alike Capsules | 0.83 | 1.41 | 2.36 |
Profile of Mood States (POMS) Subscale: Confusion-Bewilderment. Ranges from 0 to 28 with higher levels indicating higher levels of confusion/bewilderment. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 2.47 | 2.95 | 3.46 |
| Progesterone 200 mg Look-alike Capsules | 2.31 | 2.98 | 2.80 |
Profile of Mood States (POMS) Subscale: Depression-Dejection. This subscale ranges from 0-60 with higher levels indicating greater depression/dejection. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 1.09 | 1.30 | 1.66 |
| Progesterone 200 mg Look-alike Capsules | 0.64 | 0.88 | 1.81 |
Profile of Mood States (POMS) Subscale: Fatigue. This subscale ranges from 0 to 28 with higher scores indicating higher levels of fatigue. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 2.17 | 2.84 | 3.66 |
| Progesterone 200 mg Look-alike Capsules | 1.77 | 3.63 | 3.10 |
Profile of Mood States (POMS) Subscale: Tension-Anxiety. This subscale ranges from 0-28 with higher levels indicating greater tension/anxiety. (NCT01954966)
Timeframe: Day 2 (pre and post scan), Day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post- 2nd scan | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 2.88 | 3.55 | 4.85 |
| Progesterone 200 mg Look-alike Capsules | 2.57 | 3.11 | 3.70 |
Withdrawal symptoms will be measured using the Nicotine Withdrawal Symptoms Checklist (NWSC). The scale ranges from a minimum of 0 to a maximum of 28, with higher scores indicating greater withdrawal (more withdrawal symptoms, higher intensity/severity of withdrawal). (NCT01954966)
Timeframe: Day 1 (pre and post smoking session, day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nicotine withdrawal symptoms checklist (NWSC); day 1 pre 1st smoking session | Nicotine withdrawal symptoms checklist (NWSC); day 1 post 1st smoking session | Nicotine withdrawal symptoms checklist (NWSC); day 2 pre-scan | Nicotine withdrawal symptoms checklist (NWSC); day 2 post-scan | Nicotine withdrawal symptoms checklist (NWSC); day 3 abstinence AM | Nicotine withdrawal symptoms checklist (NWSC); day 3 abstinence PM | Nicotine withdrawal symptoms checklist (NWSC); day 4 abstinence AM | Nicotine withdrawal symptoms checklist (NWSC); day 4 abstinence PM | Nicotine withdrawal symptoms checklist (NWSC); day 5 pre-smoking | Nicotine withdrawal symptoms checklist (NWSC); day 5 post-smoking | |
| Progesterone 200 mg Capsules | 6.00 | 4.84 | 5.67 | 5.37 | 7.07 | 6.99 | 7.33 | 7.19 | 7.01 | 4.60 |
| Progesterone 200 mg Look-alike Capsules | 6.15 | 4.48 | 4.92 | 5.25 | 7.62 | 7.88 | 7.66 | 7.32 | 7.34 | 4.82 |
Craving will also be assessed using the Tiffany Questionnaire for Smoking Urges. It ranges from 32 to 224 with higher scores indicated higher levels of smoking urges/craving. (NCT01954966)
Timeframe: Day 1 (pre smoking session, day 3 (PM), day 4 (PM), day 5 (pre smoking session)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1; pre-1st smoking session | Day 3; abstinence PM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | |
| Progesterone 200 mg Capsules | 143.45 | 138.46 | 139.11 | 146.22 |
| Progesterone 200 mg Look-alike Capsules | 140.31 | 140.77 | 135.88 | 141.08 |
Visual Analog Scale (VAS) question: Anxious. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 16.69 | 15.02 | 20.20 | 16.38 | 18.46 | 15.88 | 17.81 | 16.26 |
| Progesterone 200 mg Look-alike Capsules | 15.62 | 12.65 | 17.38 | 20.23 | 15.08 | 15.63 | 19.05 | 15.30 |
Visual Analog Scale (VAS) question: Calm. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 74.35 | 73.15 | 65.65 | 58.92 | 60.23 | 65.47 | 67.60 | 69.27 |
| Progesterone 200 mg Look-alike Capsules | 76.52 | 69.23 | 61.15 | 52.44 | 57.97 | 62.48 | 61.02 | 70.52 |
Visual Analog Scale (VAS) question: Depressed. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 3.97 | 4.99 | 6.43 | 4.61 | 5.51 | 5.67 | 2.64 | 2.53 |
| Progesterone 200 mg Look-alike Capsules | 2.87 | 5.55 | 6.85 | 4.58 | 5.17 | 5.73 | 5.26 | 4.89 |
Visual Analog Scale (VAS) question: Drowsy. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 16.63 | 24.25 | 17.14 | 24.71 | 19.56 | 19.84 | 23.01 | 20.45 |
| Progesterone 200 mg Look-alike Capsules | 14.29 | 30.17 | 15.43 | 24.36 | 18.32 | 20.50 | 21.01 | 21.45 |
Visual Analog Scale (VAS) question: Energetic. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 54.86 | 55.18 | 56.14 | 56.13 | 55.62 | 53.45 | 51.47 | 54.79 |
| Progesterone 200 mg Look-alike Capsules | 67.01 | 21.03 | 58.11 | 50.12 | 54.89 | 56.77 | 56.64 | 54.70 |
Visual Analog Scale (VAS) question: Happy. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 76.62 | 70.98 | 66.22 | 65.10 | 62.76 | 61.99 | 66.59 | 70.07 |
| Progesterone 200 mg Look-alike Capsules | 79.70 | 71.34 | 64.04 | 61.30 | 60.58 | 63.95 | 63.46 | 67.87 |
Visual Analog Scale (VAS) question: Headache. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 6.50 | 5.74 | 9.15 | 8.86 | 10.88 | 11.83 | 9.05 | 11.93 |
| Progesterone 200 mg Look-alike Capsules | 7.59 | 9.39 | 14.71 | 10.93 | 7.70 | 12.78 | 13.36 | 11.67 |
Visual Analog Scale (VAS) question: Heartburn. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 3.11 | 4.30 | 5.46 | 6.00 | 7.31 | 5.51 | 4.33 | 4.56 |
| Progesterone 200 mg Look-alike Capsules | 2.35 | 4.06 | 3.27 | 4.55 | 6.50 | 5.56 | 5.30 | 6.37 |
Visual Analog Scale (VAS) question: Hunger. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 34.60 | 28.63 | 24.88 | 27.72 | 27.94 | 25.57 | 28.22 | 28.63 |
| Progesterone 200 mg Look-alike Capsules | 40.23 | 22.20 | 33.40 | 31.95 | 34.64 | 29.27 | 35.22 | 32.61 |
Visual Analog Scale (VAS) question: Irritable. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 7.50 | 13.20 | 24.80 | 23.97 | 30.79 | 26.50 | 23.23 | 13.45 |
| Progesterone 200 mg Look-alike Capsules | 5.71 | 13.01 | 24.56 | 25.49 | 29.58 | 30.11 | 22.96 | 15.52 |
Visual Analog Scale (VAS) question: Nauseous. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 5.52 | 6.31 | 6.01 | 8.07 | 6.07 | 6.60 | 6.51 | 8.00 |
| Progesterone 200 mg Look-alike Capsules | 4.92 | 5.43 | 10.44 | 9.85 | 8.22 | 10.29 | 10.34 | 11.41 |
Visual Analog Scale (VAS) question: Nervous. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 13.24 | 10.91 | 7.19 | 9.56 | 9.36 | 10.83 | 10.79 | 7.64 |
| Progesterone 200 mg Look-alike Capsules | 10.26 | 8.46 | 8.22 | 9.24 | 11.37 | 10.66 | 12.15 | 11.94 |
Visual Analog Scale (VAS) question: Relaxed. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 72.66 | 67.77 | 63.87 | 57.69 | 57.83 | 63.46 | 62.45 | 67.99 |
| Progesterone 200 mg Look-alike Capsules | 73.87 | 63.65 | 55.85 | 54.08 | 55.37 | 63.45 | 67.65 | 67.55 |
Visual Analog Scale (VAS) question: Sad. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 3.95 | 6.77 | 5.67 | 4.36 | 8.54 | 7.32 | 3.87 | 2.95 |
| Progesterone 200 mg Look-alike Capsules | 2.09 | 4.48 | 10.51 | 9.07 | 8.47 | 8.65 | 12.47 | 5.92 |
Visual Analog Scale (VAS) question: Headache. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 54.17 | 50.61 | 51.43 | 48.14 | 49.67 | 50.48 | 52.74 | 54.26 |
| Progesterone 200 mg Look-alike Capsules | 57.46 | 51.46 | 50.34 | 47.04 | 50.71 | 49.27 | 56.19 | 53.12 |
Visual Analog Scale (VAS) question: Tired. Scale ranges from 0 to 100 with higher levels indicating greater intensity of symptom/feeling. (NCT01954966)
Timeframe: Day 2 (pre and post scan), day 3 (AM and PM), day 4 (AM and PM), day 5 (pre and post smoking session)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 2; pre-1st scan | Day 2; post-2nd scan | Day 3; abstinence AM | Day 3; abstinence PM | Day 4; abstinence AM | Day 4; abstinence PM | Day 5; after scan, pre-smoking | Day 5; after smoking | |
| Progesterone 200 mg Capsules | 24.15 | 29.67 | 21.64 | 30.82 | 31.73 | 30.69 | 33.94 | 31.22 |
| Progesterone 200 mg Look-alike Capsules | 18.62 | 40.92 | 27.24 | 35.53 | 27.99 | 28.51 | 32.06 | 34.79 |
2 reviews available for creatine and Alcoholism
| Article | Year |
|---|---|
Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.
Topics: Alcoholism; Animals; Appetite Stimulants; Aspartic Acid; Brain; Choline; Cocaine; Creatine; Glutamic | 2010 |
N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease.
Topics: Aging; Alcoholism; Amyotrophic Lateral Sclerosis; Aspartic Acid; Biomarkers; Brain; Brain Injuries; | 2006 |
3 trials available for creatine and Alcoholism
| Article | Year |
|---|---|
Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Animals; Aspartic Acid; C-Reactive Protein; Choline; Creatine; Humans; | 2022 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking.
Topics: Adult; Alcoholism; Aspartic Acid; Choline; Creatine; gamma-Aminobutyric Acid; Humans; Magnetic Reson | 2006 |
26 other studies available for creatine and Alcoholism
| Article | Year |
|---|---|
BDNF rs6265 Met carriers with alcohol use disorder show greater age-related decline of N-acetylaspartate in left dorsolateral prefrontal cortex.
Topics: Alcoholism; Brain-Derived Neurotrophic Factor; Creatine; Dorsolateral Prefrontal Cortex; Humans; Mar | 2023 |
Glutamate concentration in the anterior cingulate cortex in alcohol dependence: association with alcohol withdrawal and exploration of contribution from glutamatergic candidate genes.
Topics: Adult; Aged; Alcoholism; Case-Control Studies; Creatine; Female; GATA4 Transcription Factor; Genetic | 2018 |
A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Cerebral Cortex; Choline; Comorbidity; Creatine; gamma-Amino | 2014 |
Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Choline; Chronic Dise | 2016 |
Alcohol abuse and acute behavioural disturbances in a 24-year-old patient. Diagnosis: Marchiafava-Bignami disease (MBD).
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Aspartic Acid; Choline; Corpus Callosum; Crea | 2009 |
Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study.
Topics: Adult; Age Factors; Alcoholism; Analysis of Variance; Aspartic Acid; Bipolar Disorder; Brain; Comorb | 2010 |
Brain metabolite changes in alcoholism: localized proton magnetic resonance spectroscopy study of the occipital lobe.
Topics: Adult; Alcoholism; Aspartic Acid; Case-Control Studies; Choline; Creatine; Humans; Image Interpretat | 2011 |
Brain injury and recovery following binge ethanol: evidence from in vivo magnetic resonance spectroscopy.
Topics: Alcoholism; Analysis of Variance; Animals; Aspartic Acid; Body Weight; Brain Injuries; Brain Mapping | 2010 |
Metabolite levels in the brain reward pathway discriminate those who remain abstinent from those who resume hazardous alcohol consumption after treatment for alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Creatine; Female; Follow-Up Studies; Huma | 2010 |
Body mass index is associated with brain metabolite levels in alcohol dependence--a multimodal magnetic resonance study.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Aspartic Acid; Body Mass Index; Brain; Choline; Creatine; | 2010 |
Effects of alcoholism and gender on brain metabolism.
Topics: Adult; Age Factors; Alcoholism; Aspartic Acid; Brain; Creatine; Female; Frontal Lobe; Humans; Inosit | 2003 |
Proton MR spectroscopic studies of chronic alcohol exposure on the rat brain.
Topics: Alcoholism; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine; Magnetic Resonance Sp | 2003 |
Central pontine myelinolysis in chronic alcoholism demonstrated by magnetic resonance imaging and spectroscopy.
Topics: Alcoholism; Choline; Creatine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; | 2004 |
[Clinical aspects of acute intoxication with ethanol].
Topics: Adolescent; Adult; Age Factors; Aged; Alcoholic Intoxication; Alcoholism; Coma; Creatine; Creatine K | 2004 |
Cortical NAA deficits in HIV infection without dementia: influence of alcoholism comorbidity.
Topics: Adult; Alcoholism; Aspartic Acid; Brain Mapping; Case-Control Studies; Cerebral Cortex; Choline; Com | 2005 |
Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Alcoholism; Aspartic Acid; Brain Chemistry; Creatine; Female; Functional Laterality; Gl | 2005 |
Get sober; stay sober.
Topics: Alcoholism; Aspartic Acid; Brain; Brain Diseases; Choline; Creatine; Humans; Magnetic Resonance Spec | 2007 |
Manifestations of early brain recovery associated with abstinence from alcoholism.
Topics: Adult; Alcoholism; Aspartic Acid; Atrophy; Attention; Brain; Brain Chemistry; Cerebellum; Choline; C | 2007 |
Alteration of brain metabolites in young alcoholics without structural changes.
Topics: Adult; Alcoholism; Brain; Brain Mapping; Choline; Creatine; Female; Glutamic Acid; Humans; Magnetic | 2007 |
Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder.
Topics: Adult; Alcoholism; Algorithms; Aspartic Acid; Atrophy; Combat Disorders; Comorbidity; Conditioning, | 2008 |
Treatment of symptomatic porphyria by venesection.
Topics: Adult; Aged; Alcoholism; Bloodletting; Creatine; Female; Humans; In Vitro Techniques; Iron; Male; Mi | 1967 |
Evidence of vitamin E deficiency in patients with malabsorption or alcoholism and the effects of therapy.
Topics: Adult; Aged; Alcoholism; Creatine; Creatinine; Feces; Female; Hemolysis; Humans; Lipids; Malabsorpti | 1967 |
Chemical pathology in brain white matter of recently detoxified alcoholics: a 1H magnetic resonance spectroscopy investigation of alcohol-associated frontal lobe injury.
Topics: Adult; Alcoholism; Aspartic Acid; Brain; Choline; Creatine; Female; Frontal Lobe; Humans; Inositol; | 2001 |
Effects of chronic alcohol consumption on regulation of myocardial protein synthesis.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Alcoholism; Animals; Body We | 2001 |
[Rhabdomyolysis as a complication of chronic alcoholism. Observations in 19 cases].
Topics: Adult; Aged; Alcoholism; Creatine; Creatine Kinase; Electrolytes; Female; Humans; Kidney Failure, Ch | 1986 |
Elevation of the pressure in the abdominal inferior vena cava as a cause of a hepatorenal syndrome in cirrhosis.
Topics: Adult; Aged; Alcoholism; Blood Pressure; Blood Urea Nitrogen; Creatine; Glomerular Filtration Rate; | 1966 |